文献速递类风湿关节炎

预测类风湿关节炎的最佳治疗

Predicting best treatment in rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2023-11-22

本综述讨论类风湿关节炎精准医学进展:滑膜活检批量RNA测序结合组织学与深度临床表型分析,揭示不同致病通路与基因表达亚组;R4RA等活检驱动的随机对照试验支持基于基因特征的机器学习预测模型,用于预测不同治疗的反应及难治状态。

要点

  • 滑膜活检RNA测序可将RA分为少免疫纤维型、弥漫髓系型和淋巴髓系型三个基因表达亚组,与组织学分型相关。
  • R4RA试验中患者随机接受利妥昔单抗或托珠单抗,分析鉴定出与应答相关的基因特征及难治状态相关细胞类型如DKK3+成纤维细胞。
  • 基于特定基因特征的机器学习预测模型可预测未来治疗应答及难治状态。

核心结论

  • 滑膜活检RNA测序在理解RA疾病内型及鉴定预测预后和未来治疗反应的滑膜基因特征方面取得实质性进展。

研究设计与样本

  • 本综述讨论近期类风湿关节炎精准医学研究的进展。
  • 方法包括对RA个体滑膜活检进行批量RNA测序,结合组织学和深度临床表型分析。
  • 活检驱动的随机对照试验包括R4RA和即将开展的STRAP试验。

主要发现

  • 在早期关节炎病理生物学队列(PEAC)中,基因表达分析显示个体可分为三个基因表达亚组,与组织学标志物定义的组织病理型相关:少免疫纤维型以成纤维细胞为特征且无免疫炎症细胞;弥漫髓系型以巨噬细胞流入为特征;淋巴髓系型以B细胞存在为界定,但通常含有复杂炎症浸润伴异位淋巴结构形成。
  • 在R4RA活检驱动的随机对照试验中,患者被随机分配至利妥昔单抗或托珠单抗。
  • 对治疗前后滑膜活检的综合分析鉴定出与致病通路相关的应答基因特征,这些特征可随时间追踪。
  • 鉴定出一组真难治患者,他们在研究前抗TNF治疗失败(这是入组标准),随后在试验期间对两种试验生物制剂均失败。
  • RNA测序分析和数字空间分析鉴定出特定细胞类型,包括DKK3+成纤维细胞,与难治状态相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis (RA), 40% of patients show poor clinical response, and there is an imperative to unravel the molecular pathways and mechanisms underlying non-response and disease progression. 5-20% of RA individuals do not respond to all current medications including biologic and targeted therapies, which suggests that distinct pathogenic processes underlie multi-drug refractoriness. OBJECTIVES: In this brief review we discuss advances from recent studies in precision medicine in rheumatoid arthritis. METHODS: Bulk RNA-Sequencing of synovial biopsies from RA individuals combined with histology and deep clinical phenotyping has revealed substantial insights into divergent pathogenic pathways which lead to disease progression and illuminated mechanisms underlying failure to response to specific treatments. Biopsy-driven randomised controlled trials, such as R4RA and the forthcoming STRAP trial, have enabled the development of machine learning predictive models for predicting response to different therapies. RESULTS: In the Pathobiology of Early Arthritis Cohort (PEAC), gene expression analysis showed that individuals could be classified into three gene expression subgroups which correlated with histopathotypes defined by histological markers: pauci-immune fibroid pathotype characterised by fibroblasts and an absence of immune inflammatory cells; diffuse-myeloid pathotype characterised by macrophage influx; and the lympho-myeloid pathotype delineated by the presence of B cells, but typically containing a complex inflammatory infiltrate with ectopic lymphoid structure formation. In the R4RA biopsy-driven randomised controlled trial, patients were randomised to either rituximab or tocilizumab. Comprehensive analysis of synovial biopsies pre/post-treatment identified gene signatures of response associated with pathogenic pathways which could be tracked over time. A group of true refractory patients were identified who had failed anti-TNF prior to the study (it was an entry criterion) and then subsequently failed both trial biologics during the trial. RNA-Seq analysis and digital spatial profiling identified specific cell types including DKK3+ fibroblasts as being associated with the refractory state. We identified machine learning predictive models based on specific gene signatures which were able to predict future response to therapy as well as the refractory state. CONCLUSIONS: RNA-sequencing of synovial biopsies has enabled substantial progress in understanding disease endotypes in RA and identifying synovial gene signatures which predict prognosis and future response to treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lewis MJ. Predicting best treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2023. PMID: 38008706. doi:10.1016/j.semarthrit.2023.152329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。